Inhibrx Stock Fundamentals
| INBX Stock | USD 13.98 0.06 0.43% |
Inhibrx fundamentals help investors to digest information that contributes to Inhibrx's financial success or failures. It also enables traders to predict the movement of Inhibrx Stock. The fundamental analysis module provides a way to measure Inhibrx's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inhibrx stock.
At this time, Inhibrx's Interest Expense is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 30.9 M in 2024, despite the fact that Net Loss is likely to grow to (124.2 M). Inhibrx | Select Account or Indicator |
Inhibrx Company Profit Margin Analysis
Inhibrx's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Inhibrx Profit Margin | 1,020 % |
Most of Inhibrx's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inhibrx is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Inhibrx Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, Inhibrx has a Profit Margin of 1.02 K%. This is 9196.72% lower than that of the Biotechnology sector and notably lower than that of the Health Care industry. The profit margin for all United States stocks is notably lower than that of the firm.
Inhibrx Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Inhibrx's current stock value. Our valuation model uses many indicators to compare Inhibrx value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Inhibrx competition to find correlations between indicators driving Inhibrx's intrinsic value. More Info.Inhibrx is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Inhibrx's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Inhibrx's earnings, one of the primary drivers of an investment's value.Did you try this?
Run My Watchlist Analysis Now
My Watchlist AnalysisAnalyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
| All Next | Launch Module |
Inhibrx ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inhibrx's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inhibrx's managers, analysts, and investors.Environmental | Governance | Social |
Inhibrx Fundamentals
| Return On Equity | -20.31 | ||||
| Return On Asset | -0.57 | ||||
| Profit Margin | 1,020 % | ||||
| Current Valuation | 7.88 M | ||||
| Shares Outstanding | 14.48 M | ||||
| Shares Owned By Insiders | 23.54 % | ||||
| Shares Owned By Institutions | 67.49 % | ||||
| Number Of Shares Shorted | 976.67 K | ||||
| Price To Book | 1.13 X | ||||
| Price To Sales | 119.96 X | ||||
| Revenue | 1.8 M | ||||
| Gross Profit | (107.99 M) | ||||
| EBITDA | (206.69 M) | ||||
| Net Income | (241.36 M) | ||||
| Cash And Equivalents | 176.38 M | ||||
| Cash Per Share | 4.52 X | ||||
| Total Debt | 210.14 M | ||||
| Debt To Equity | 4.22 % | ||||
| Current Ratio | 7.51 X | ||||
| Book Value Per Share | 15.15 X | ||||
| Cash Flow From Operations | (193.31 M) | ||||
| Short Ratio | 14.06 X | ||||
| Earnings Per Share | 119.39 X | ||||
| Target Price | 15.0 | ||||
| Number Of Employees | 166 | ||||
| Beta | 2.88 | ||||
| Market Capitalization | 202.37 M | ||||
| Total Asset | 307.89 M | ||||
| Retained Earnings | (613.73 M) | ||||
| Working Capital | 239.05 M | ||||
| Net Asset | 307.89 M |
About Inhibrx Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inhibrx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibrx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibrx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 149.4 K | 141.9 K | |
| Total Revenue | 1.8 M | 1.7 M | |
| Cost Of Revenue | 1.2 M | 1.1 M | |
| Stock Based Compensation To Revenue | 13.80 | 14.49 | |
| Sales General And Administrative To Revenue | 16.32 | 17.14 | |
| Research And Ddevelopement To Revenue | 106.47 | 111.79 | |
| Capex To Revenue | 2.55 | 2.68 | |
| Revenue Per Share | 0.04 | 0.04 | |
| Ebit Per Revenue | (121.79) | (115.70) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Inhibrx Stock Analysis
When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.